Astel­las forges a $390M deal to buy a biotech fo­cused on Ronald Evans’ ‘ex­er­cise-in-a-pill’ tech

For years now, Salk’s Ron Evans — a cel­e­brat­ed se­r­i­al en­tre­pre­neur in sci­en­tif­ic cir­cles — has been con­cen­trat­ing on the po­ten­tial of a new path­way for turn­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER